Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Dopamine; Quetiapine Fumarate; Raclopride

Criteria

Inclusion Criteria:

• Normal MRI scan

• Body mass index 19-30 kg/m2 and weight of 50-100 kg

• Clinically normal physical findings, medical history and laboratory values

Exclusion Criteria:

• Trauma or sickness last 2 weeks before the first PET examination.

• A history or presence of neurological, haematological, psychiatric, gastrointestinal, hepatic, pulmonary, renal disease or other condition as judged by the Investigator

• Any previous participation in a PET study

• Subjects suffer from claustrophobia